Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,680,000 shares, a decrease of 34.4% from the February 28th total of 2,560,000 shares. Based on an average trading volume of 540,400 shares, the short-interest ratio is currently 3.1 days. Approximately 3.7% of the company’s shares are short sold.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Generation Bio in a report on Friday, March 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 price objective on shares of Generation Bio in a research note on Monday, March 17th. Finally, Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research note on Friday, March 14th.

Generation Bio Stock Performance

Shares of Generation Bio stock traded down $0.02 during trading hours on Monday, reaching $0.41. The company’s stock had a trading volume of 365,901 shares, compared to its average volume of 258,381. The stock has a market cap of $27.14 million, a P/E ratio of -0.18 and a beta of 2.72. The company’s 50 day simple moving average is $0.65 and its 200 day simple moving average is $1.38. Generation Bio has a one year low of $0.40 and a one year high of $4.65.

Generation Bio (NASDAQ:GBIO) last posted its earnings results on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The firm had revenue of $4.19 million during the quarter, compared to the consensus estimate of $2.92 million. On average, sell-side analysts predict that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at Generation Bio

In other Generation Bio news, Director Anthony G. Quinn acquired 85,000 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was bought at an average price of $0.97 per share, with a total value of $82,450.00. Following the completion of the transaction, the director now directly owns 299,286 shares of the company’s stock, valued at approximately $290,307.42. The trade was a 39.67 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 21.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GBIO. Intech Investment Management LLC bought a new position in Generation Bio during the 4th quarter valued at $25,000. Squarepoint Ops LLC bought a new position in Generation Bio during the fourth quarter valued at about $70,000. Integrated Wealth Concepts LLC bought a new position in Generation Bio during the fourth quarter valued at about $77,000. Aegis Wealth Management LLC acquired a new position in Generation Bio during the fourth quarter worth about $94,000. Finally, Millennium Management LLC bought a new stake in Generation Bio in the fourth quarter worth about $97,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.